ZyVersa Therapeutics, Inc. (ZVSA)

US — Healthcare Sector
Peers: IMMX  CNSP  EFTR  NAVB  SONN  GETR  SMX  DRMA  FOXO 

Automate Your Wheel Strategy on ZVSA

With Tiblio's Option Bot, you can configure your own wheel strategy including ZVSA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ZVSA
  • Rev/Share 0.0
  • Book/Share 2616.8453
  • PB 0.0002
  • Debt/Equity 0.0
  • CurrentRatio 0.1758
  • ROIC -0.2395

 

  • MktCap 2816339.0
  • FreeCF/Share -1562.2476
  • PFCF -0.0006
  • PE -0.0004
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -1.1193

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 5
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds
ZVSA
Published: July 08, 2025 by: GlobeNewsWire
Sentiment: Neutral

WESTON, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, today announced its entry into a warrant inducement agreement with a single institutional investor of the Company. Terms of the warrant inducement agreement include the immediate exercise of Series A-2 Warrants to purchase up to 957,200 shares of common stock (the “Series A-2 Warrants”) and Series A-3 Warrants to purchase up to 2,105,265 shares of common stock (the “Series A-3 Warrants,” and together …

Read More
image for news ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds
ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update
ZVSA
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral

WESTON, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA), a clinical-stage biopharmaceutical company specializing in first-in-class therapies for inflammatory and renal diseases, announces significant developments for Inflammasome ASC Inhibitor IC 100.

Read More
image for news ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update

About ZyVersa Therapeutics, Inc. (ZVSA)

  • IPO Date 2022-02-11
  • Website https://www.zyversa.com
  • Industry Biotechnology
  • CEO Stephen C. Glover
  • Employees 7
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.